Antimalarial drug resistance

Author(s): White NJ

Abstract

Malaria, the most prevalent and most pernicious parasitic disease of humans, is estimated to kill between one and two million people, mainly children, each year. Resistance has emerged to all classes of antimalarial drugs except the artemisinins and is responsible for a recent increase in malaria-related mortality, particularly in Africa. The de novo emergence of resistance can be prevented by the use of antimalarial drug combinations. Artemisinin-derivative combinations are particularly effective, since they act rapidly and are well tolerated and highly effective. Widespread use of these drugs could roll back malaria.

Similar Articles

Medicinal plants in therapy

Author(s): Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z

Burger's medicinal chemistry and drug discovery

Author(s): James F, Kerwin Jr.

Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial

Author(s): Dondorp A, Nosten F, Stepniewska K, Day N, White N; South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group

Artesunate versus quinine for severe falciparum malaria

Author(s): Woodrow CJ, Planche T, Krishna S

Artemisinins: activities and actions

Author(s): Haynes RK, Krishna S

Artemisone--a highly active antimalarial drug of the artemisinin class

Author(s): Haynes RK, Fugmann B, Stetter J, Rieckmann K, Heilmann HD, et al.

A single amino acid residue can determine the sensitivity of SERCAs to artemisinins

Author(s): Uhlemann AC, Cameron A, Eckstein-Ludwig U, Fischbarg J, Iserovich P, et al.

Identification of an antimalarial synthetic trioxolane drug development candidate

Author(s): Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, et al.

Synthetic studies towards halichondrins: synthesis of the C

Author(s): Aicher TD, Buszek KR, Fang FG, Forsyth CJ, Jung SH, et al.

Enabling high-throughput discovery

Author(s): Vaschetto M, Weissbrod T, Bodle D, Güner O